| HOME >> MEDICINE >> TECHNOLOGY |
To exclude amortization of commercial intangible assets related to marketed products of $83,974 and the impact of inventory step-up recorded as part of acquisition accounting of $6,289.(2)
To exclude certain start-up costs and separation benefits incurred in connection with continued efforts to enhance the company's operations.(3)
To exclude a milestone-like payment and milestone and upfront payments to partners of $23,850 and certain costs incurred in connection with continued efforts to enhance the cost structure of the company of $512.(4)
To exclude the impairment of Octreotide and Pagoclone of $22,000 and $13,000, respectively.(5)
To exclude acquisition-related costs of $70,396 as well as the impact, under purchase accounting, of a gain recorded to reflect the change in the company's current estimate of fair value, in accordance with GAAP, of the contingent consideration associated with the Indevus acquisition of $(51,420).(6)
To exclude additional interest expense as a result of adopting ASC 470-20 of $17,296 and to exclude amortization of the premium on debt acquired from Indevus of ($313).(7)
To exclude changes in fair value of financial instruments, net.(8)
To reflect the cash tax savings results from our recent acquisitions and the tax effect of the pre-tax adjustments above at applicable tax rates.Twelve Months Ended December 31, 2009 (unaudited) Actual Reported (GAAP) AdjustmentsAdjustedTotal Revenues$ 1,460,841
$
8212;$ 1,460,841Costs and expenses: Cost of revenues
375,058
(74,199)
(1)
300,859 Selling, general and administrative
534,523
(2,549)
(2)
531,974 Research and development
185,317
(77,099)
(3)
108,218Impairment of intangibles
69,000
(69,000)
(4)
—Acquisition-related items
(93,081)
93,081
(5)
̵
'/>"/>
| SOURCE Endo Pharmaceuticals Copyright©2010 PR Newswire. All rights reserved |